Abstract
BackgroundNatural products from herbal medicines have long been investigated for their potentials as cancer therapeutics. Besides the development of several herbal medicine-derived anti-cancer agents, such as paclitaxel, vincristine and podophyllotoxin, many recent laboratory findings demonstrated that brusatol, a quassinoid from the seeds of Brucea sumatrana, exhibits potent tumor suppressing effect with improved disease outcome. Our recent finding further demonstrated that brusatol synergizes with the intrinsic metabolic burden in cancer cells.Main bodyHere, we summarized the recent investigations of brusatol as an experimental therapeutic for human malignancies, such as leukemia, lung cancer, pancreatic cancer and brain tumor. We also discussed the molecular target brusatol, with a focus on the Nuclear factor erythroid 2-related factor 2 (NRF2)-guided gene transcription, as well as glutathione de novo synthesis. Further, we discussed the challenges and future applications of brusatol for cancer therapy.ConclusionIn conclusion, we believe increasing evidences have shown the value of brusatol as a novel strategy for cancer treatment, which may indicate future drug development and clinical translation.
Highlights
The quassinoid brusatol was first isolated and characterized from the seeds of Brucea sumatrana in 1968
In conclusion, we believe increasing evidences have shown the value of brusatol as a novel strategy for cancer treatment, which may indicate future drug development and clinical translation
Optimizing brusatol specificity to Nuclear factor erythroid 2-related factor 2 (NRF2) may be helpful to reduce side effect, which is currently in urgent need for future clinical applications. Collectively, these evidences revealed that brusatol is a promising anticancer compound by disrupting redox homeostasis
Summary
The quassinoid brusatol was first isolated and characterized from the seeds of Brucea sumatrana in 1968. Conclusion: In conclusion, we believe increasing evidences have shown the value of brusatol as a novel strategy for cancer treatment, which may indicate future drug development and clinical translation. We discussed the latest findings of the molecular targets of brusatol, as well as its value as a future cancer therapeutic. Application of brusatol as an experimental cancer therapeutic Brusatol was firstly evaluated as an experimental therapeutic for leukemia.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.